2 Fast-Growing Pharmaceutical Stocks to Buy Now

Incyte (INCY) reports strong operating momentum, with Q1 revenue up 21% YoY to $1.27B and adjusted EPS at $1.81 beating the $1.34 consensus, helped by Jakafi sales of $758M (+7% YoY) and Opzelura sales of $143M (+20%). The company is also reducing pipeline concentration risk via its $1.25B acquisition of Vega Therapeutics and expects four new approvals/launches through early 2027. TG Therapeutics (TGTX) is riding Briumvi momentum after raising full-year revenue guidance to $925M and first-quarter U.S. sales of $194.8M, with stock performance up nearly 90% YTD 2026. Overall, the article frames both stocks as capital-efficient biotech compounders with positive near-to-mid-term catalysts.

Analysis

INCY is the cleaner quality story: the market should increasingly treat it as a self-funded late-stage platform rather than a single-drug cash cow. If management converts pipeline breadth into even two or three credible launches, the multiple can expand because the equity stops trading on concentration risk alone; the hidden risk is that acquisition-driven pipeline filling often looks smarter on slides than in post-deal dilution and integration.

TGTX is a different setup: the stock has likely pulled forward a meaningful share of a M&A premium, which is dangerous when the asset base is still effectively anchored by one franchise. In MS, strategic value is not just growth but durability against incumbent retaliation from BIIB/NVS/SNY; a better efficacy or convenience profile matters more than headline sales momentum, so any takeout case needs proof that the SC program materially strengthens the lifecycle.

The next 1-3 months matter more for sentiment than fundamentals: INCY can grind higher on continued execution, while TGTX is vulnerable to mean reversion if there is no deal process or if growth simply normalizes. Over 6-18 months, INCY’s balance-sheet optionality and cash-flow conversion should be rewarded; TGTX needs either a strategic event or a second growth leg, otherwise the stock risks being priced like a platform when it still behaves like a single-product story. Key falsifiers are a growth miss, delayed launches, or any trial setback in the SC/MS readouts.

Key Decisions for Investors

• Long INCY on pullbacks for a 6-12 month hold; thesis is self-funded pipeline expansion and lower concentration risk. Falsify if core product growth decelerates materially or management pushes launch timing out by a full quarter.
• Short TGTX or buy 1-3 month put spreads after further extension; the setup is more momentum/takeout-dependent than fundamental. Risk/reward improves if the stock rips on no new data and implied vol stays elevated.
• Pair trade: long INCY / short TGTX, sized as a quality-vs-sentiment relative value trade over 3-6 months. This works if the market keeps rewarding durable cash flow over single-asset M&A optionality.
• Watch BIIB/NVS/SNY as read-through names for MS share defense; if any of them signal accelerating patient starts or pricing pressure, it weakens the strategic scarcity argument behind TGTX.
• Alert item, not a recommendation: if TGTX announces a credible buyer or SC data that meaningfully extends exclusivity, cover shorts immediately; absent that, treat the recent rally as over-earned.